WHISH-2-Prevent Heart Failure

NCT03099889 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49936

Last updated 2019-05-07

No results posted yet for this study

Summary

The WHISH-2-Prevent Heart Failure (HF) study is an ancillary study to the Women's Health Initiative Strong and Healthy (WHISH) exercise pragmatic trial. The WHISH-2-Prevent HF trial examines the intervention effect of physical activity (PA) on both incident HF and HF burden (recurrent HF and CVD death in those with HF) in a cost effective manner in elderly women. In addition, it will allow a dose-finding analysis to better understand the type, intensity and frequency of PA that leads to a reduced risk and burden of HF. The focus of the parent WHISH trial is on atherosclerotic cardiovascular disease and not heart failure.

Conditions

  • Physical Activity
  • Heart Failure
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure With Normal Ejection Fraction
  • Strength Training
  • Elderly
  • Women

Interventions

BEHAVIORAL

Physical Activity

Physical activity intervention based upon stage of change and social cognitive theory based interventions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH
  • Stanford University

    collaborator OTHER
  • Ohio State University

    collaborator OTHER
  • Fred Hutchinson Cancer Center

    collaborator OTHER
  • University of North Carolina, Chapel Hill

    collaborator OTHER
  • University of California, San Francisco

    collaborator OTHER
  • University of California, San Diego

    collaborator OTHER
  • University at Buffalo

    collaborator OTHER
  • Wake Forest University

    collaborator OTHER
  • Memorial Hospital of Rhode Island

    lead OTHER

Principal Investigators

  • Charles B Eaton, MD, MS · Memorial Hospital of Rhode Island

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
66 Years
Max Age
102 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-15
Primary Completion
2020-09-01
Completion
2021-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03099889 on ClinicalTrials.gov